Full Press Release Details
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of
autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately.
Dr. Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory,
and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she was one of the key leaders of successful development and execution of
clinical trials for telitacicept across four key indications systemic lupus erythematosus (SLE), Sj gren s syndrome, myasthenia gravis (MG), and rheumatoid arthritis (RA) culminating in regulatory approvals in China for the
treatment of SLE, generalized MG and RA.
At RemeGen, Dr. Zuraw built and led a cross-functional global team that managed all aspects of telitacicept
development, including clinical trial design, regulatory strategy, site engagement, and execution. She played a central role in regulatory interactions with the U.S. Food & Drug Administration, European Medicines Agency, and China s
Center for Drug Evaluation, achieving Fast Track, Breakthrough Therapy, and Orphan Drug designations for telitacicept across multiple indications.
We are delighted to welcome Qing to Vor Bio at a critical time for the company, said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman
of the Board. Her deep and diverse clinical development expertise across autoimmune and immunological diseases and with telitacicept will be invaluable as we execute on our late-stage programs. Qing s ability to lead high-performing
clinical organizations will be instrumental as we drive forward our global development programs, particularly in the U.S.
previously held senior leadership roles at Janssen Research & Development, Teva Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Biogen Inc., and Covance, Inc., where she led global clinical development programs across
rheumatology, nephrology, respiratory, and immunology. She played a key role in the U.S. FDA approval of Guselkumab for psoriatic arthritis and contributed to multiple NDA and BLA submissions across therapeutic areas. Throughout her career, she has
built and led high-performing teams to execute complex trials from early development through post-marketing.
Vor Bio is uniquely positioned to
become a leader in autoimmune therapeutics, said Dr. Zuraw. Having been intimately involved in the development of telitacicept in China from early clinical stages through to multiple approvals, I m thrilled to join the talented
team at Vor Bio to bring telitacicept to patients globally.
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept,
a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words aim, anticipate, can, continue, could, design,
enable, expect, initiate, intend, may, on-track, ongoing, plan, potential, should,
target, update, will, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking
statements in this press release include Vor Bio s statements regarding Vor Bio s development plans for telitacicept, its ability to change the treatment landscape for patients with autoimmune conditions and other statements that are not
historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption Risk Factors included in
Vor Bio s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor
Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Media & Investor Contacts: